| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
177.44(B) |
| Last
Volume: |
9,460,177 |
Avg
Vol: |
8,347,593 |
| 52
Week Range: |
$95.48 - $140.97 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 425 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
257,397 |
328,897 |
710,682 |
1,253,752 |
| Total Sell Value |
$33,385,709 |
$41,721,826 |
$80,912,514 |
$130,099,211 |
| Total People Sold |
6 |
6 |
6 |
7 |
| Total Sell Transactions |
15 |
24 |
40 |
56 |
| End Date |
2025-11-02 |
2025-08-01 |
2025-01-31 |
2024-02-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oday Daniel Patrick |
Chairman & CEO |
• • – |
2026-01-28 |
4 |
AS |
$139.54 |
$1,398,911 |
D/D |
(10,000) |
556,698 |
|
2% |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2026-01-23 |
4 |
AS |
$135.00 |
$15,611,400 |
D/D |
(115,640) |
566,698 |
|
4% |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2026-01-23 |
4 |
OE |
$66.01 |
$7,633,396 |
D/D |
115,640 |
682,338 |
|
- |
|
| Bluestone Jeffrey |
Director |
– • – |
2026-01-20 |
4 |
AS |
$123.50 |
$617,500 |
D/D |
(5,000) |
8,920 |
|
14% |
|
| Bluestone Jeffrey |
Director |
– • – |
2026-01-20 |
4 |
OE |
$67.45 |
$337,250 |
D/D |
5,000 |
13,920 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• – – |
2026-01-15 |
4 |
AS |
$124.31 |
$372,930 |
D/D |
(3,000) |
150,503 |
|
17% |
|
| Mercier Johanna |
Chief Commercial Officer |
• – – |
2026-01-15 |
4 |
AS |
$124.31 |
$372,930 |
D/D |
(3,000) |
103,221 |
|
17% |
|
| Berger Dietmar |
Chief Medical Officer |
• – – |
2026-01-02 |
4 |
D |
$121.60 |
$844,390 |
D/D |
(6,944) |
9,382 |
|
- |
|
| Berger Dietmar |
Chief Medical Officer |
• – – |
2026-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,326 |
16,326 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2025-12-29 |
4 |
AS |
$124.83 |
$1,248,272 |
D/D |
(10,000) |
566,698 |
|
14% |
|
| Dickinson Andrew D |
Chief Financial Officer |
• – – |
2025-12-15 |
4 |
AS |
$122.00 |
$366,000 |
D/D |
(3,000) |
153,503 |
|
19% |
|
| Mercier Johanna |
Chief Commercial Officer |
• – – |
2025-12-15 |
4 |
AS |
$122.00 |
$366,000 |
D/D |
(3,000) |
106,221 |
|
19% |
|
| Mercier Johanna |
Chief Commercial Officer |
• – – |
2025-12-10 |
4 |
D |
$121.34 |
$220,111 |
D/D |
(1,814) |
109,221 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• – – |
2025-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,842 |
111,035 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2025-12-10 |
4 |
D |
$121.34 |
$598,328 |
D/D |
(4,931) |
576,698 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2025-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,426 |
581,629 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• – – |
2025-12-10 |
4 |
D |
$121.34 |
$211,738 |
D/D |
(1,745) |
156,503 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• – – |
2025-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,693 |
158,248 |
|
- |
|
| Bluestone Jeffrey |
Director |
– • – |
2025-11-28 |
4 |
S |
$125.08 |
$625,400 |
D/D |
(5,000) |
8,920 |
|
-11% |
|
| Bluestone Jeffrey |
Director |
– • – |
2025-11-28 |
4 |
OE |
$64.92 |
$324,600 |
D/D |
5,000 |
13,920 |
|
- |
|
| Kramer Kelly A. |
Director |
– • – |
2025-11-28 |
4 |
AS |
$127.10 |
$356,516 |
D/D |
(2,805) |
1,339 |
|
13% |
|
| Kramer Kelly A. |
Director |
– • – |
2025-11-28 |
4 |
OE |
$81.00 |
$227,205 |
D/D |
2,805 |
4,144 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2025-11-28 |
4 |
AS |
$125.91 |
$1,265,444 |
D/D |
(10,000) |
571,203 |
|
13% |
|
| Kramer Kelly A. |
Director |
– • – |
2025-11-26 |
4 |
AS |
$127.11 |
$356,671 |
D/D |
(2,806) |
1,339 |
|
11% |
|
| Kramer Kelly A. |
Director |
– • – |
2025-11-26 |
4 |
OE |
$81.00 |
$227,286 |
D/D |
2,806 |
4,145 |
|
- |
|
936 Records found
|
|
Page 1 of 38 |
|
|
2.40 (1.72%) 
